Patient Care

AATD- Overview

AATD occurs in approximately 1 in 3000-5000 people. Severe AATD affects an estimated 100,000 individuals in the USA. The estimate is, however, that less than 6% AATD individuals are currently identified.
AATD is often first diagnosed as Chronic Obstructive Pulmonary Disease (COPD) (link to COPD). But it is not uncommon that these patients also have airway diseases including bronchiectasis (link to bronchiectasis) and asthma (link to asthma). The World Health Organization (WHO), American Thoracic Society (ATS), and the European Respiratory Society (ERS) recommend that everyone with COPD and asthma should be tested for AATD. Identified patients may be candidates for alpha one replacement therapy.
Contacts at UM

UM has highly specialized experts for patients with AATD as the research of Dr. Michael Campos focuses on AATD. Dr. Adam Wanner is currently also serving as the scientific director of the Alpha 1 Foundation.

The University of Miami Health System offers several ways to request an appointment with these physicians. You can make an appointment by calling Monday through Friday from 7:30 a.m. to 6:00 p.m., Eastern Time at 305-243-4000 or toll-free 1-800-432-0191. Appointments can also be requested online at:

For patients with AATD interested in participation of clinical studies, please follow the link to the division’s research page (link to research) for further contact information.